Bicara Therapeutics Inc. Prepaid Expense and Other Assets, Current
Bicara Therapeutics Inc. (BCAX) had Prepaid Expense and Other Assets, Current of $6.56 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-11
- 2026-06-30: Prepaid Expense and Other Assets, Current $6.56M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $5.16M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $7.25M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $7.21M.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2026-06-30 | $6.56M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $5.16M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $7.25M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $7.21M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $7.79M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $8.69M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $12.82M 10-K · filed 2026-03-30 |
| 2024-09-30 | $756.00K 10-Q · filed 2024-11-12 |
| 2023-12-31 | $633.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |